Australia Asthma Therapeutics Market Size, Share, By Drug Class (Anti-inflammatories, Bronchodilators, and Combination therapy), By Route of Administration (Oral, Inhaled, and Intravenous), Australia Asthma Therapeutics Market Insights, Industry Trend, Forecasts to 2035.

Australia Asthma Therapeutics Market Insights Forecasts to 2035

• Australia Asthma Therapeutics Market Size 2024: USD 568.3 Mn
• Australia Asthma Therapeutics Market Size 2035:  USD 1340.7 Mn
• Australia Asthma Therapeutics Market CAGR 2024: 8.12%
• Australia Asthma Therapeutics Market Segments: Drug Class and Route of Administration

The Australia Asthma Therapeutics Market encompasses the industry that handles the creation, manufacturing, and distribution of both medications and devices designed to treat and manage asthma. The main objective of these therapeutics is to lessen the swelling of the air passages, enhance the breathing capacity, alleviate the symptoms, and avoid the occurrence of serious asthma attacks (exacerbations). High asthma prevalence, robust government subsidies, easier access to inhaled medications, greater awareness, and increasing use of advanced combination and biologic treatments are all contributing factors to Australia's developing asthma therapeutics market.

Australia maintains the asthma medications market at a high level through the Pharmaceutical Benefits Scheme (PBS), which limits the cost of medicines that the patients pay to approximately AUD 30 for each prescription. Among the government initiatives are Medicare financing and AUD 1.47 million granted to Asthma Australia for its programs, which increase accessibility and affordability, thereby improving the management of asthma throughout the country.

The recent news is that Dupixent (dupilumab) will be available on Australia's PBS for kids with severe asthma starting from September 2025, thus broadening access to the advanced biologic therapy. Moreover, the nationwide management of severe asthma will be facilitated by the updated monoclonal antibody guidance and the introduction of new inhalers (such as Easyhaler).

Market Dynamics of the Australia Asthma Therapeutics Market:

The Australia asthma therapeutics market is driven by a very high prevalence of asthma amongst the population (millions of Australians live with this condition), as well as the government's provision of the Pharmaceutical Benefits Scheme (PBS), which makes treatments for asthma more affordable. Other factors contributing to the growth of the asthma therapeutics market include an increased awareness of the benefits of early diagnosis and a desire to achieve good control over long-term asthma, and as combination inhalers and biologic therapies are becoming more widely adopted for use in combination with preventative medications for asthma, improvements are continuing to be made for personalised therapy solutions and innovations in providing preventative respiratory care.

The Australia asthma therapeutics market is restrained by the very high costs associated with the purchase of advanced biologic therapy drugs, strict reimbursement and regulatory requirements for such drugs, issues with treatment adherence, and side effects experienced as a result of long-term use of medication for managing asthma, all of which leads to limiting access to treatment options for patients suffering from asthma, despite the government providing strong support from the healthcare system.

With the growth of biologicals (such as IL 4/13 monoclonal antibodies, IL 5, and related products) as treatment options for severe asthma. On top of that, there's digital health technology, which has created innovations in smart inhalers and adherence apps, personalized medicine using predictive biomarkers, and novel ways of delivering drugs to patients in ways that both improve drug effectiveness and increase patient compliance with their inhaler use. There's going to continue to be a focus on prevention. Pediatric Asthma is where the market will also see significant growth opportunities, and continued developments in the use of real-world evidence to support new drugs.

Market Segmentation

The Australia Asthma Therapeutics Market share is classified into drug class and route of administration.

By Drug Class:

The Australia asthma therapeutics market is divided by drug class into anti-inflammatories, bronchodilators, and combination therapy. Among these, the combination therapy segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Clinical recommendations supporting inhaled corticosteroid, bronchodilator combos, better symptom control, fewer exacerbations, increased patient adherence, and the widespread availability of combination inhalers that are subsidized under the Pharmaceutical Benefits Scheme (PBS) are the main factors driving this dominance.

By Route of Administration:

The Australia asthma therapeutics market is divided by route of administration into oral, inhaled, and intravenous. Among these, the inhaled segment accounted for the largest share in 2024 and is projected to grow at a significant CAGR during the forecast period. The widespread use of inhalers as first-line asthma therapy, quick medication delivery straight to the lungs, increased therapeutic efficacy, less systemic adverse effects, and strong clinical guideline support all contribute to this.

Competitive Analysis:

The report offers the appropriate analysis of the key organisations/companies involved within the Australia asthma therapeutics market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market. 

Top Key Companies in Australia Asthma Therapeutics Market:

• Medical Developments International Ltd
• Pharmaxis Ltd
• Adherium Limited
• 4DMedical Ltd
• Diag-Nose.io
• Mayne Pharma Group Ltd
• Vita Life Sciences Ltd
• IDT Australia Ltd
• EBOS Group Ltd
• Others

Recent Developments in Australia Asthma Therapeutics Market:

In September 2025, Dupixent (dupilumab) became a part of the PBS list for children aged 6–11 years with severe asthma, thus making advanced biologic therapy accessible to more patients through subsidy.

In September 2025, the Australian Asthma Handbook was made available, presenting new nationwide clinical guidelines for asthma management.

In March 2025, the National Asthma Council Australia reworked its information and resources regarding monoclonal antibody therapy to assist doctors with treatment decisions for severe asthma.

In September 2024, inhaled asthma medicines were included in the 60-day PBS prescription program, which made it possible for asthmatic patients to get two inhalers for the price of one, thus making them more accessible and less costly.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the Australia, regional, and country levels from 2020 to 2035. Spherical insights has segmented the Australia asthma therapeutics market based on the below-mentioned segments:

Australia Asthma Therapeutics Market, By Drug Class

• Anti-inflammatories
• Bronchodilators
• Combination therapy

Australia Asthma Therapeutics Market, By Route of Administration

• Oral
• Inhaled
• Intravenous